<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152707</url>
  </required_header>
  <id_info>
    <org_study_id>LUM-ABU-SPLENDOR X-2019-01</org_study_id>
    <nct_id>NCT04152707</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Splendor X for Hair Removal</brief_title>
  <official_title>Clinical Evaluation of Splendor X for Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumenis Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumenis Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least 40 healthy male or female subjects that wish to remove their hair will be enrolled
      to this study.

      Each subject will receive five treatments at 6-8 weeks intervals. Subjects will return for
      follow-up visits at 3, 6, 9, and 12 months after the last treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair reduction</measure>
    <time_frame>3 months follow up</time_frame>
    <description>change in number of hairs at 3 months following the last treatment as compared to baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hair Remval</condition>
  <arm_group>
    <arm_group_label>Splendor X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Splendor X</intervention_name>
    <description>The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).</description>
    <arm_group_label>Splendor X</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to read, understand and provide written Informed Consent;

          2. All skin types: I-VI

          3. Male or female

          4. Age - 18-50 years of age

          5. Having one suitable treatment areas (legs, back, Chest or abdomen) with dark brown or
             black hair appropriate for hair removal;

          6. Interested in laser hair removal treatment for permanent hair reduction in the
             suitable area

          7. Able and willing to comply with the treatment/follow-up schedule and requirements;

          8. Women of child-bearing age are required to be using a reliable method of birth control
             at least 3 months prior to enrollment and throughout the course of the study.

        Exclusion Criteria:

          1. Pregnant, expectation of pregnancy, postpartum or nursing (&lt;6 months);

          2. Participation in another clinical study

          3. Active infections in the treated area;

          4. Dysplastic nevi in the treatment area;

          5. Tattoos in the treatment area;

          6. Current cancer, history of skin cancer or pre-cancerous lesions at the treatment
             areas;

          7. History of keloid scars anywhere on the body or scar formation in the treatment area ;
             or at risk of Keloid scars

          8. Active cold sores, open lacerations or abrasions in the treated area;

          9. Herpes simplex in the treatment area

         10. Prior skin treatment with laser or other devices on the same treated areas prior to
             study enrollment or during the course of the study

         11. Significant concurrent skin conditions or any inflammatory skin conditions;

         12. Chronic or cutaneous viral, fungal, or bacterial diseases;

         13. Intense tan, Deep suntan, recent suntan within 2 weeks, sunburn or artificially tanned
             skin;

         14. Use of medications, herbal supplements, perfumes or cosmetics that may affect
             sensitivity to light or change skin metabolism

         15. Skin lesions

         16. Bleeding coagulopathies or use of anticoagulants

         17. Hormonal disorders that may affect hair growth;

         18. Immunosuppressive diseases, including AIDS and HIV infection, or use of
             immunosuppressive medications; or other auto-immune dsorders.

         19. Livedo reticularis;

         20. Uncontrolled systemic diseases such as diabetes;

         21. Use of Accutaneâ„¢ (Isotretinoin) within the past 6 month;

         22. Erythema ab igne, when identified treatments should be discontinued;

         23. Photosensitivity disorder that can be exacerbated by laser or intense light (such as
             Epilepsy).

         24. Poor wound healing;

         25. Unable or unlikely to refrain from artificial tanning, including the use of tanning
             booths, prior (at least 6 week) and during the course of the evaluation;

         26. Previous skin procedures on requested treatment area (botox, fillers , peels , lasers
             etc. )

         27. Mechanical or chemical hair removal in the treated area within 6 weeks before the
             laser treatment

         28. Subjects who do not desire permanent hair reduction in the areas to be treated

         29. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Rohrer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SkinCare Physicians</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Chapas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Union Square Laser Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Rohrer, M.D</last_name>
      <phone>617-731-1600</phone>
      <email>TRohrer@skincarephysicians.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Square Laser Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Chapas, M.D</last_name>
      <phone>212-366-5400</phone>
      <email>drchapas@unionderm.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

